Actively Recruiting
Long-term Observational Study of Dupilumab Treatment for Atopic Dermatitis in Patients 6 Years and Older Evaluating Symptoms, Quality of Life, and Disease Control Over Two Years
Led by Sanofi · Updated on 2026-02-12
900
Participants Needed
55
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting a prospective, non-interventional observational study to understand how patients aged 6 years and older with atopic dermatitis AD respond to treatment with dupilumab in everyday medical practice. The study aims to characterize these patients by examining their medical history, demographic and disease-related features, associated allergic conditions, other type 2 inflammation diseases, and their past and current treatments. The study will also assess the long-term effectiveness and safety of dupilumab over two years, focusing on disease control and quality of life.
CONDITIONS
Brief Title
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
